The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
WITHDRAWN: It’s in the genes: A study of men at high genetic risk of developing prostate cancer (PCa).
 
Anna Couvillon
No Relationships to Disclose
 
Nikhil Pramod
No Relationships to Disclose
 
Baris Turkbey
No Relationships to Disclose
 
Peter Choyke
No Relationships to Disclose
 
Shisi He
No Relationships to Disclose
 
Sonja Berndt
No Relationships to Disclose
 
Inger Rosner
No Relationships to Disclose
 
Robert Sidlow
No Relationships to Disclose
 
Michael Mullane
No Relationships to Disclose
 
Veda Giri
Stock and Other Ownership Interests - Novopyxis (I)
 
Todd Morgan
Consulting or Advisory Role - ClevelandDx; Foundation Medicine; Stratify Genomics; Tempus
Research Funding - MDxHealth (Inst)
 
Heather Cheng
Consulting or Advisory Role - Janssen Oncology
Research Funding - Clovis Oncology (Inst); Janssen (Inst); Phosplatin Therapeutics (Inst); Sanofi (Inst)
Patents, Royalties, Other Intellectual Property - UpToDate
 
Sandeep Gurram
No Relationships to Disclose
 
Yi Liu
No Relationships to Disclose
 
Kathleen Calzone
No Relationships to Disclose
 
James Gulley
Research Funding - Astellas Medivation (Inst); Bavarian Nordic (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); ImmunityBio (Inst); Incyte (Inst); Janssen Oncology (Inst); Kite, a Gilead company (Inst); Marengo Therapeutics (Inst); Merck (Inst); NextCure (Inst); PDS Biotechnology (Inst); Pfizer (Inst); Precigen (Inst); Syndax (Inst); Syntrix Biosystems (Inst)
Patents, Royalties, Other Intellectual Property - COMBINATION PDL1 AND TGF-BETA BLOCKADE IN PATIENTS WITH HPV+ MALIGNANCIES Publication number: 20200062849 Abstract: The invention provides a method of inhibiting a malignancy associated with human papilloma virus (HPV) comprising administering to a subje
 
William Figg
Research Funding - Astellas Pharma (Inst); Biocompatibles (Inst); Celgene (Inst); Nerviano Medical Sciences (Inst); NovaRX (Inst); Pfizer (Inst); Propella Therapeutics (Inst); TRACON Pharma (Inst)
 
Peter Pinto
No Relationships to Disclose
 
William Dahut
Leadership - Dexcom (I)
Stock and Other Ownership Interests - Dexcom (I)
 
Fatima Karzai
No Relationships to Disclose